A team of researchers has developed a novel method to enhance the precision of cancer treatment using gold nanoparticles tagged with DNA barcodes. A team of researchers from the National University of ...
Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous ...
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction ...
(MENAFN- GlobeNewsWire - Nasdaq) STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting ...
The MarketWatch News Department was not involved in the creation of this content. SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results